Switch theme
Sign up to access all valuation multiples
Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a presence while generating the vast majority of its revenue in India. The company aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, creams, injectables, capsules, liquids, and lotion. The company's manufacturing plants are located in India.
1979
7.8K+
LTM Revenue $539M
LTM EBITDA $151M
$3.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ajanta Pharma has a last 12-month revenue of $539M and a last 12-month EBITDA of $151M.
In the most recent fiscal year, Ajanta Pharma achieved revenue of $483M and an EBITDA of $146M.
Ajanta Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ajanta Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $431M | $483M | XXX | XXX | XXX |
| Gross Profit | $278M | $301M | XXX | XXX | XXX |
| Gross Margin | 65% | 62% | XXX | XXX | XXX |
| EBITDA | $102M | $146M | XXX | XXX | XXX |
| EBITDA Margin | 24% | 30% | XXX | XXX | XXX |
| Net Profit | $82.8M | $68.3M | XXX | XXX | XXX |
| Net Margin | 19% | 14% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 18, 2025, Ajanta Pharma's stock price is INR 2695 (or $31).
Ajanta Pharma has current market cap of INR 337B (or $3.9B), and EV of INR 329B (or $3.8B).
See Ajanta Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.8B | $3.9B | XXX | XXX | XXX | XXX | $0.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 18, 2025, Ajanta Pharma has market cap of $3.9B and EV of $3.8B.
Ajanta Pharma's trades at 7.1x LTM EV/Revenue multiple, and 25.3x LTM EBITDA.
Analysts estimate Ajanta Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ajanta Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.8B | XXX | XXX | XXX |
| EV/Revenue | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | 25.7x | XXX | XXX | XXX |
| P/E | 37.4x | XXX | XXX | XXX |
| P/E/Growth | 2.3x | XXX | XXX | XXX |
| EV/FCF | 43.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAjanta Pharma's NTM/LTM revenue growth is 13%
Ajanta Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $30K for the same period.
Over next 12 months, Ajanta Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ajanta Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ajanta Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 42% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 41% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $30K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 48% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ajanta Pharma acquired XXX companies to date.
Last acquisition by Ajanta Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Ajanta Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ajanta Pharma founded? | Ajanta Pharma was founded in 1979. |
| Where is Ajanta Pharma headquartered? | Ajanta Pharma is headquartered in India. |
| How many employees does Ajanta Pharma have? | As of today, Ajanta Pharma has 7.8K+ employees. |
| Is Ajanta Pharma publicy listed? | Yes, Ajanta Pharma is a public company listed on BOM. |
| What is the stock symbol of Ajanta Pharma? | Ajanta Pharma trades under 532331 ticker. |
| When did Ajanta Pharma go public? | Ajanta Pharma went public in 2000. |
| Who are competitors of Ajanta Pharma? | Similar companies to Ajanta Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ajanta Pharma? | Ajanta Pharma's current market cap is $3.9B |
| What is the current revenue of Ajanta Pharma? | Ajanta Pharma's last 12-month revenue is $539M. |
| What is the current EBITDA of Ajanta Pharma? | Ajanta Pharma's last 12-month EBITDA is $151M. |
| What is the current EV/Revenue multiple of Ajanta Pharma? | Current revenue multiple of Ajanta Pharma is 7.1x. |
| What is the current EV/EBITDA multiple of Ajanta Pharma? | Current EBITDA multiple of Ajanta Pharma is 25.3x. |
| What is the current revenue growth of Ajanta Pharma? | Ajanta Pharma revenue growth between 2023 and 2024 was 12%. |
| Is Ajanta Pharma profitable? | Yes, Ajanta Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
